Journal Mobile Options
Table of Contents
Vol. 133, No. 3, 2004
Issue release date: March 2004

Fcγ Receptors on Mast Cells: Activatory and Inhibitory Regulation of Mediator Release

Tkaczyk C. · Okayama Y. · Metcalfe D.D. · Gilfillan A.M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Mast cell activation and subsequent release of proinflammatory mediators are primarily a consequence of aggregation of the high affinity receptors for IgE (FcεRI) on the mast cell surface following antigen-dependent ligation of FcεRI-bound IgE. However, data obtained from rodent and human mast cells have revealed that IgG receptors (FcγR) can both promote and inhibit mast cell activation. These responses appear to be species and/or mast cell phenotype dependent. In CD34+-derived human mast cells exposed to interferon-γ, FcγRI is upregulated, FcγRII is expressed but not upregulated, and FcγRIII is not expressed. In contrast, in mouse mast cells, FcγRII and FcγRIII receptors are expressed, whereas FcγRI is not. Aggregation of FcγRI on human mast cells promotes mediator release in a manner generally similar to that observed following FcεRI aggregation. Aggregation of FcγRIIb in mouse mast cells fails to influence cellular processes; however, when coligated with FcεRI, signaling events thus activated downregulate antigen-dependent mediator release. These divergent responses are a consequence of different motifs contained within the cytosolic tails of the signaling subunits of these receptors and the specific signaling molecules recruited by these receptors following ligation. The studies described imply that data obtained in rodent models regarding the influence of FcγRs on mast cells may not be directly translatable to the human. The exploitation of FcγRs for a potential therapy for the treatment of allergic disorders is discussed in this context.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033–1079.
  2. Schwartz LB: Heterogeneity of human mast cells; in Kaliner MA, Metcalfe DD (eds): The Mast Cell in Health and Disease. New York, Dekker, 1993, pp 219–236.
  3. Ihle JN, Keller J, Oroszlan S, Henderson LE, Copeland TD, Fitch F, Prystowsky MB, Goldwasser E, Schrader JW, Palaszynski E, Dy M, Lebel B: Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 1983;131:282–287.
  4. Levi-Schaffer F, Austen KF, Gravallese PM, Stevens RL: Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci USA 1986;83:6485–6488.
  5. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams DE: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235–243.
  6. Galli SJ, Kitamura Y: Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am J Pathol 1987;127:191–198.
  7. Furitsu T, Saito H, Dvorak AM, Schwartz LB, Irani AM, Burdick JF, Ishizaka K, Ishizaka T: Development of human mast cells in vitro. Proc Natl Acad Sci USA 1989;86:10039–10043.
  8. Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB: Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 1992;80:3009–3021.
  9. Mitsui H, Furitsu T, Dvorak AM, Irani AM, Schwartz LB, Inagaki N, Takei M, Ishizaka K, Zsebo KM, Gillis, Ishizaka T: Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA 1993;90:735–739.
  10. Kirshenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo K, Metcalfe DD: Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148:772–777.
  11. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K: Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992;80:2237–2245.
  12. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD: Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+ and expresses aminopeptidase N (CD13). Blood 1999;94:2333–2342.
  13. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M, Uzumaki H, Takahashi G, Tsuji K, Nakahata, T: Selective growth of human mast cell induced by steel factor, Il-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 1996;157:343–350.
  14. Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–494.

    External Resources

  15. Blank U, Ra C, Miller L, Metzger H, Kinet JP: Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989;337:187–189.
  16. Lin S, Cicala C, Scharenberg AM, Kinet JP: The Fc(epsilon)RI beta subunit functions as an amplifier of Fc(epsilon)RI gamma-mediated cell activation signals. Cell 1996;85:985–995.
  17. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP: Allergy-associated FcRβ is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998;8:517–529.
  18. Donnadieu E, Jouvin MH, Rana S, Moffatt MF, Mockford EH, Cookson WO, Kinet JP: Competing functions encoded in the allergy-associated F(c)epsilonRIbeta gene. Immunity 2003;18:665–674.
  19. Scharenberg AM, Lin S, Cueno B, Yamamur H, Kinet JP: Reconstitution of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by receptor clustering. EMBO J 1995;14:3385–3394.
  20. Reth M: Antigen receptor tail clue. Nature 1989;338:383–384.

    External Resources

  21. Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH: The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 1995;3:635–646.
  22. Jouvin MHE, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet JP: Differential control of the tyrosine kinases lyn and syk by the two signalling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994;269:5918–5925.
  23. Chen T, Repetto B, Chizzonite R, Pullar C, Burghardt C, Dharm E, Zhao Z, Carroll, R Nunes P, Basu M, Danho W, Visnick M, Kochan J, Waugh D, Gilfillan AM: Interaction of phosphorylated FcepsilonRIgamma immunoglobulin receptor tyrosine activation motif-based peptides with dual and single SH2 domains of p72syk. Assessment of binding parameters and real time binding kinetics. J Biol Chem 1996;271:25308–25315.
  24. Sheets ED, Holowka D, Baird B: Membrane organization in immunoglobulin E receptor signaling. Curr Opin Chem Biol 1999;3:95–99.

    External Resources

  25. Brown DA, London E: Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998;14:111–136.
  26. Baird B, Sheets ED, Holowka D: How does the plasma membrane participate in cellular signaling by receptors for immunoglobulin E? Biophys Chem 1999;82:109–119.

    External Resources

  27. Saitoh S, Arudchandran R, Manetz TS, Zhang W, Sommers CL, Love PE, Rivera J, Samelson LE: LAT is essential for FcεRI-mediated mast cell activation. Immunity 2000;12:525–535.
  28. Brdicka T, Imrich M, Angelisova P, Brdickova N, Horvath O, Spicka J, Hilgert I, Luskova P, Draber P, Novak P, Engels N, Wienands J, Simeoni L, Osterreicher J, Aguado E, Malissen M, Schraven B, Horejsi V: Non-T cell activation linker (NTAL): A transmembrane adaptor protein involved in immunoreceptor signaling. J Exp Med 2002;196:1617–1626.
  29. Janssen E, Zhu M, Zhang W, Koonpaew S, Zhang W: LAB: A new transmembrane-associated adaptor molecule in B cell activation. Nat Immunol 2003;4:117–123.
  30. Saitoh S, Odom S, Gomez G, Sommers CL, Young HA, Rivera J, Samelson LE: The four distal tyrosines are required for LAT-dependent signaling in FcepsilonRI-mediated mast cell activation. J Exp Med 2003;198:831–843.
  31. Zhang C, Baumgartner RA, Yamada K, Beaven MA: Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J Biol Chem 1997;272:13397–13402.
  32. Parravicini V, Gadina M, Kovarova M, Odom S, Gonzales-Espinosa C, Furumoto Y, Saitoh S, Samelson LE, O’Shea JJ, Rivera J: Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 2002;3:741–748.
  33. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, Maeda-Yamamoto M, Lowell CA, Rawlings DJ, Witte ON, Kawakami T: Redundant and opposing functions of two tyrosine kinases, btk and lyn, in mast cell activation. J Immunol 2000;165:1210–1219.
  34. Tkaczyk C, Beaven MA, Brachman SM, Metcalfe DD, Gilfillan AM: The phospholipase Cγ-dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol-kinase. J Biol Chem 2003;278:48474–48484.
  35. Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T: Functions of Bruton’s tyrosine kinase in mast and B cells. J Leukoc Biol 1999;65:286–290.
  36. Okayama Y, Kirshenbaum AS, Metcalfe DD: Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: Up-regulation by IFN-γ. J Immunol 2000;164:4332–4339.
  37. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF: Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via FcγR bridging in mouse mast cells. J Immunol 1992;148:868–871.
  38. Daeron M, Malbec O, Latour S, Arock M, Fridman WH: Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995;95:577–585.
  39. Malbec O, Fridman WH, Daeron M: Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB. J Immunol 1999;162:4424–4429.
  40. Daeron M: Building up the family of ITIM-bearing negative coreceptors. Immunol Lett 1996;54:73–76.
  41. Ernst LK, Van de Winkel JG, Chiu IM, Anderson CL: Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem 1992;267:15692–15700.
  42. Ernst LK, Duchemin AM, Miller KL, Anderson CL: Molecular characterization of six variants Fcγ receptor class I (CD64) transcripts. Mol Immunol 1998;35:943–954.
  43. Heijnen IA, Van de Winkel JG: Human IgG Fc receptors. Int Rev Immunol 1997;16:29–55.
  44. Pan LY, Mendel DB, Zurlo J, Guyre PM: Regulation of steady state level of Fc gamma RI mRNA by IFN-gamma and dexamethasone in human monocytes, neutrophils and U-937 cells. J Immunol 1990;145:267–275.
  45. Okayama Y, Hagaman DD, Woolhiser M, Metcalfe DD: Further characterization of FcγRII and FcγRIII expression by cultured human mast cells. Int Arch Allergy Immunol 2001;124:155–157.
  46. Okayama Y, Hagaman DD, Metcalfe DD: A comparison of mediators released or generated by IFN-γ-treated human mast cells following aggregation of FcγRI or FcεRI. J Immunol 2001;166:4705–4712.
  47. Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD: IgG-dependent activation of human mast cells following up-regulation of FcγRI by IFN-γ. Eur J Immunol 2001;31:3298–3307.
  48. Woolhiser MR, Brockow K, Metcalfe DD: Activation of human mast cells by aggregated IgG through FcγRI: Additive effects of C3a. Clin Immunol, in press.
  49. Barker JN, Allen MH, MacDonald DM: Alterations induced in normal human skin by in vivo interferon-gamma. Br J Dermatol 1990;122:451–458.
  50. Tkaczyk C, Okayama Y, Woolhiser MR, Hagaman DD, Gilfillan AM, Metcalfe DD: Activation of human mast cells through the high affinity IgG receptor. Mol Immunol 2002;38:1289–1293.
  51. Okayama Y, Tkaczyk C, Metcalfe DD, Gilfillan AM: Comparison of Fc epsilon RI- and Fc gamma RI-mediated degranulation and TNF-alpha synthesis in human mast cells: Selective utilization of phosphatidylinositol-3-kinase for Fc gamma RI-induced degranulation. Eur J Immunol 2003;33:1450–1459.
  52. Tkaczyk C, Beaven MA, Brachman SM, Metcalfe DD, Gilfillan AM: The phospholipase Cγ1-dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem 2003;278:48474–48484.
  53. Ernst LK, Duchemin AM, Anderson CL: Association of the high-affinity receptor for IgG (Fc gamma RI) with the gamma subunit of the IgE receptor. Proc Natl Acad Sci USA 1993;90:6023–6027.
  54. Daeron M: Fc receptor biology. Annu Rev Immunol 1997;15:203–234.
  55. Edberg JC, Yee AM, Rakshit DS, Chang DJ, Gokhale JA, Indik ZK, Schreiber AD, Kimberly RP: The cytoplasmic domain of human FcγRIα alters the functional properties of FcγRI-chain receptor complex. J Biol Chem 1999;274:30328–30333.
  56. Katz HR, Lobell RB: Expression and function of FγR in mouse mast cells. Int Arch Allergy Immunol 1995;107:76–78.
  57. Dastych J, Hardison MC, Metcalfe DD: Aggregation of low affinity IgG receptors induces mast cell adherence to fibronectin: Requirement for the common FcR gamma-chain. J Immunol 1997;158:1803–1809.
  58. Katz HR, Arm JP, Benson AC, Austen KF: Maturation-related changes in the expression of FcγRII and FcγRIII on mouse mast cells derived in vitro and in vivo. J Immunol 1990;145:3412–3417.
  59. Lobell RB, Austen KF, Katz HR: FcγR-mediated endocytosis and expression of cell surface FcγRIIb1 and FcγRIIb2 by mouse bone marrow culture-derived progenitor mast cells. J Immunol 1994;152:811–818.
  60. Van de Winkel JG, Anderson CL: Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991;49:511–524.
  61. Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, Oliver JM: Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. J Allergy Clin Immunol 2000;106:337–348.
  62. Hogarth PM, Witort E, Hulett MD, Bonnerot C, Even J, Fridman WH, McKenzie IFC: Structure of the mouse βFcγ receptor II gene. J Immunol 1991;146:369–376.
  63. Daeron M, Vivier E: Biology of immunoreceptor tyrosine-based inhibition motif-bearing molecules. Curr Top Microbiol Immunol 1999;244:1–12.
  64. Daeron M, Malbec O, Latour S, Bonnerot C, Segal DM, Fridman WH: Distinct intracytoplasmic sequences are required for endocytosis and phagocytosis via murine FcγRII in mast cells. Int Immunol 1993;5:1393–1401.
  65. Fong DC, Malbec O, Arock M, Cambier JC, Fridman WH, Daeron M: Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated FcγRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett 1996;54:83–91.
  66. Chong HJ, Bouton LA, Bailey DP, Wright H, Ramirez C, Gharse A, Oskeritzian C, Xia HZ, Zhu J, Paul WE, Kepley C, Schwartz LR: IL-4 selectively enhances FcγRIII expression and signaling on mouse mast cells. Cell Immunol 2003;224:65–73.
  67. Brown MA, Tanzola MB, Robbie-Ryan M: Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol 2002;38:1373–1378.
  68. Secor VH, Secor WE, Gutekunst CA, Brown MA: Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000;191:805–812.
  69. Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA: Both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J Immunol 2003;170:1630–1634.
  70. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF: Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE. Proc Natl Acad Sci USA 1996;93:10809–10814.
  71. Xu R, Abramson J, Fridkin M, Pecht I: SH2 domain-containing inositol polyphosphate 5′-phosphatase is the main mediator of the inhibitory action of the mast cell function-associated antigen. J Immunol 2001;167:6394–6402.
  72. Kinet JP: The high affinity IgE receptor (FcεRI): From physiology to pathology. Annu Rev Immunol 1999;17:931–972.
  73. Malbec O, Schmitt C, Bruhns P, Krystal G, Fridman WH, Daeron M: Src homology 2 domain-containing inositol 5-phophatase 1 mediates cell cycle arrest by FcgammaRIIB. J Biol Chem 2001;276:30381–30391.
  74. Wang LL, Blasioli J, Plas DR, Thomas ML, Yokoyama WM: Specificity of SH2 domains of SH-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B. J Immunol 1999;162:1318–1323.
  75. Rohschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM: Structure, function, and biology of SHIP proteins. Genes Dev 2000;14:505–520.
  76. Kimura T, Zhang J, Sagawa K, Sakaguchi K, Appella E, Siraganian RP: Syk independent tyrosine phosphorylation and association of the protein tyrosine phosphatase SHP-1 and SHP-2 with the high affinity IgE receptor. J Immunol 1997;159:4426–4434.
  77. Xie ZH, Zhang J, Siraganian RP: Positive regulation of c-Jun N-terminal kinase and TNF-α production but not histamine release by SHP-1 in RBL-2H3 mast cells. J Immunol 2000;164:1521–1528.
  78. Osborne MA, Dalton S, Kochan JP: The yeast tribrid system – Genetic detection of trans-phosphorylated ITAM-SH2-interactions. Biotechniques 1995;13:1474–1478.
  79. Lesourne R, Bruhns P, Fridman WH, Daeron M: Insufficient phosphorylation prevents Fc gamma RIIB from recruiting the SH2 domain containing protein-tyrosine phosphatase SHP-1. J Biol Chem 2001;276:6327–6336.
  80. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A: A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med 2002;8:518–521.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50